Drugs / DB107-FC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06504381 | Jan 2025 → Jan 2028 expected | glioblastoma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06264388 | May 2024 → May 2034 expected | anaplastic astrocytoma | Ashish Shah | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB107-FC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06504381 ↗ |
| Route | Oral | “three times by mouth every day” NCT06264388 ↗ |